Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Thomas Nydam"'
Autor:
Pascal, Hammel, Jill, Lacy, Fabienne, Portales, Alberto, Sobrero, Beatriz, García-Paredes, Edward, Kim, Fernando, Rivera, Luis, Manzano Jose, Eric, Terrebonne, Venu, Bathini, Scot, Dowden, Jamil, Asselah, Jack, Shiansong Li, Thomas, Nydam, Louis, Kayitalire, Philip, Philip
Publikováno v:
In Annals of Oncology June 2016 27 Supplement 2:ii78-ii78
Autor:
Christophe Borg, Jamil Asselah, Teng Jin Ong, Thomas Nydam, Jill Lacy, Pascal Hammel, Muhammad Wasif Saif, Fabienne Portales, Jose Luis Manzano Mozo, Philip A. Philip, Roberto Pazo-Cid, Javier Sastre, Daniel Lopez-Trabada, E. Terrebonne, Fernando Rivera, Jack Shiansong Li, Ahmed Zakari, Scot Dowden, Alberto Sobrero, Edward J. Kim, Venu Bathini
Publikováno v:
The lancet. Gastroenterologyhepatology. 5(3)
Summary Background Treatment options for patients with unresectable locally advanced pancreatic cancer are scarce. Results from a subanalysis of the phase 3 MPACT trial in metastatic pancreatic cancer suggested potential activity of nab-paclitaxel pl
Autor:
Kaushal Mishra, Erin Allen-Freda, Dana E. Rathkopf, George Wilding, Joel Picus, Thomas Nydam, Howard I. Scher, Arif Hussain, Kim N. Chi, Maria Grazia Porro, Susan Ellard
Publikováno v:
Cancer Chemotherapy and Pharmacology. 72:537-544
Panobinostat, a pan-deacetylase inhibitor, increases acetylation of proteins associated with growth and survival of malignant cells. This phase 2 study evaluated the efficacy of intravenous (IV) panobinostat in patients with castration-resistant pros
Autor:
William F. Wade, Doug Demian, Jerome L. Gabriel, B. George Barisas, Thomas Nydam, Shyam Yadati, Terri K. Wade
Publikováno v:
Immunology Letters. 67:47-55
Class II dimers of dimers are predicted to have functional significance in antigen presentation. The putative contact amino acids of the I-Ak class II dimer of dimers have been identified by molecular modeling based on the DR1 crystal structure (Nyda
Publikováno v:
Cancer chemotherapy and pharmacology. 70(4)
Elucidating the metabolic profile of anticancer agent panobinostat is essential during drug development. Disposition, metabolism, and excretion profiles were characterized using trace radiolabeled (14)C-panobinostat in four patients with advanced can
Publikováno v:
Journal of Clinical Oncology. 27:2549-2549
2549 Background: Panobinostat (PAN), a hydroxamic acid derivative, is a potent pan-deacetylase inhibitor, demonstrating anti-tumor activities in a wide variety of preclinical models and showing promising clinical activity. This study elucidates the m
Autor:
Kim N. Chi, Thomas Nydam, A. Fandi, Dana E. Rathkopf, Joshi J. Alumkal, Howard I. Scher, Nicholas J. Vogelzang, Sebastien J. Hotte, M. Agrawal, Ulka N. Vaishampayan
Publikováno v:
Journal of Clinical Oncology. 27:5064-5064
5064 Background: Panobinostat (LBH589) is a potent pan-deacetylase inhibitor that has demonstrated activity in both in vivo and in vitro prostate cancer models. Methods: An open-label, multicenter, dose-finding trial of i.v. panobinostat given on Day
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.